New Data Confirms Efficacy in Masses 2cm or Smaller

MELBOURNE, Australia, April 30, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118). (PRNewsfoto/Telix Pharmaceuticals Limited) The results were featured in a late-breaking oral presentation delivered on […]
See full article New Data Confirms Efficacy in Masses 2cm or Smaller by Pet News 2Day
#PetFinancialNews
Comments
Post a Comment